Gilead Sciences Inc (GILD)

72.78
0.31 0.43
NASDAQ : Health Care
Prev Close 72.47
Open 71.78
Day Low/High 71.55 / 72.90
52 Wk Low/High 77.92 / 120.37
Volume 13.05M
Avg Volume 9.62M
Exchange NASDAQ
Shares Outstanding 1.32B
Market Cap 95.33B
EPS 12.40
P/E Ratio 6.72
Div & Yield 1.88 (2.60%)

Latest News

'Yuge' Sector Rotation Will Continue

'Yuge' Sector Rotation Will Continue

What's in, what's out and who should thrive in the new political landscape.

'Mad Money' Lightning Round: Gilead Sciences, Celgene, Express Scripts

'Mad Money' Lightning Round: Gilead Sciences, Celgene, Express Scripts

Jim Cramer says he prefers Celgene to Gilead, and Walgreens Boots Alliance to Express Scripts.

Jim Cramer's 'Mad Money' Recap: Investors See Washington Going Pro-Business

Jim Cramer's 'Mad Money' Recap: Investors See Washington Going Pro-Business

Jim Cramer remains a fan of industrials, transports, banks and domestic oil producers.

Hedge Funds Hate These 5 Huge Stocks -- Should You Sell Them?

Hedge Funds Hate These 5 Huge Stocks -- Should You Sell Them?

The real story is in the stocks the pros hate.

Some 'January Effect' Stock Picks

Some 'January Effect' Stock Picks

Small-caps could also benefit from abating tax-loss selling.

'Mad Money' Lightning Round: Jim Cramer Sees Steel Companies Shining

'Mad Money' Lightning Round: Jim Cramer Sees Steel Companies Shining

WOR is in a sweet spot for this rally, and NUE looks good, too, says Jim Cramer.

Jim Cramer's 'Mad Money' Recap: Expect More Earnings Surprises

Jim Cramer's 'Mad Money' Recap: Expect More Earnings Surprises

The number and magnitude of earnings surprises has a big impact on the markets, says Jim Cramer.

Biotech Stocks May be Cheap But Large Scale M&A May Elude the Sector

Biotech Stocks May be Cheap But Large Scale M&A May Elude the Sector

Investors in biotech stocks appear to be happy with a Trump win and Mizuho's senior biotech analyst says companies in the sector could continue to climb in 2017.

Facebook, Home Depot, Disney: Doug Kass' Views

Facebook, Home Depot, Disney: Doug Kass' Views

Doug Kass shares his thoughts on contrariness and his takeaways and observations on the market.

No to Closed-End Muni Bond Funds; Cara on a Run: Best of Kass

No to Closed-End Muni Bond Funds; Cara on a Run: Best of Kass

In highlights from this week's trading diary and posts, Kass tells us about how to say no to closed-end muni bond funds and why Cara Therapeutics is on a run.

2 Small-Cap Biotech Buyout Targets

2 Small-Cap Biotech Buyout Targets

With the election resolved, biotech could be ripe for consolidation.

New Trades in Preparation for Tomorrow's Options Expiration

Close out and roll recommendations on trades expiring Friday.

Don't Count on a Rally for Gilead

Don't Count on a Rally for Gilead

I would look for GILD to try to stabilize in the $70-$80 area before a more durable uptrend.

Hey Gilead, Stop Developing Drugs and Start Buying Biotech Companies -- Now!

Hey Gilead, Stop Developing Drugs and Start Buying Biotech Companies -- Now!

For as much as we love and respect you, Gilead, the current situation is unacceptable. The once great and mighty biotech Gilead cannot trade at a 6x forward earnings multiple!

Gilead Sciences Announces Promotion Of James R. Meyers To Executive Vice President, Worldwide Commercial Operations

Gilead Sciences Announces Promotion Of James R. Meyers To Executive Vice President, Worldwide Commercial Operations

Gilead Sciences, Inc. (NASDAQ: GILD) today announced the promotion of James R.

Gilead Announces Top-Line Results From Two Phase 3 Studies Evaluating Momelotinib For Patients With Myelofibrosis

Gilead Announces Top-Line Results From Two Phase 3 Studies Evaluating Momelotinib For Patients With Myelofibrosis

Gilead Sciences, Inc. (Nasdaq: GILD) today announced top-line results from two Phase 3 clinical trials (SIMPLIFY 1 and 2) evaluating momelotinib, an investigational inhibitor of Janus kinase (JAK) compared to ruxolitinib or...

Here Are 2 Excellent Dividend-Paying Drug Stocks to Buy Right Now

Here Are 2 Excellent Dividend-Paying Drug Stocks to Buy Right Now

Two pharmaceutical companies, Gilead Sciences and Merck, offer some of the best yields in their sector.

Gilead Sciences To Present At The Annual Piper Jaffray Healthcare Conference On Tuesday, November 29

Gilead Sciences To Present At The Annual Piper Jaffray Healthcare Conference On Tuesday, November 29

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that John F.

Phase 2 Data For Selonsertib In Nonalcoholic Steatohepatitis (NASH) Presented At The Liver Meeting® 2016

Phase 2 Data For Selonsertib In Nonalcoholic Steatohepatitis (NASH) Presented At The Liver Meeting® 2016

Gilead Sciences (Nasdaq:GILD) today announced detailed results from an open-label Phase 2 trial evaluating the investigational apoptosis signal-regulating kinase 1 (ASK1) inhibitor selonsertib (formerly GS-4997) alone or in...

European CHMP Adopts Positive Opinion For Gilead's Vemlidy® (Tenofovir Alafenamide, TAF) For The Treatment Of Chronic Hepatitis B Virus Infection

European CHMP Adopts Positive Opinion For Gilead's Vemlidy® (Tenofovir Alafenamide, TAF) For The Treatment Of Chronic Hepatitis B Virus Infection

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion on the...

Stocks Surge After Trump Victory

Stocks Surge After Trump Victory

Stocks close at session highs on Wednesday as the idea of a Trump presidency settles in. Financial and health care sectors lead the market.

Stocks Maintain Solid Gains After Donald Trump Wins the White House

Stocks Maintain Solid Gains After Donald Trump Wins the White House

Stocks post solid gains Wednesday after plunging overnight following Donald Trump's surprising victory in the U.S. presidential race.

Gilead Is Going Strong

Gilead Is Going Strong

Gilead is taking part in the huge move in the biotech sector.

Stocks Turn Positive After Trump's Surprising Election Win

Stocks Turn Positive After Trump's Surprising Election Win

Stocks turn positive Wednesday as investors gauge a Donald Trump presidency on markets. Drug, biotech and financial stocks jump.

Drug and Biotech Stocks Rise as Price Clampdown Fears Ease Under Trump Presidency (Updated)

Drug and Biotech Stocks Rise as Price Clampdown Fears Ease Under Trump Presidency (Updated)

How health care investors deal with Donald Trump as the next U.S. president and Republicans maintaining control of Congress is hard to forecast because few envisioned this scenario playing out.

Stock Futures Remain Sharply Lower Following Trump's Victory

Stock Futures Remain Sharply Lower Following Trump's Victory

Stock futures fall on Wednesday as voters elect Donald Trump as the next U.S. president.

'Mad Money' Lightning Round: Ollie's Bargain Outlet, Walmart Are Winners

'Mad Money' Lightning Round: Ollie's Bargain Outlet, Walmart Are Winners

Jim Cramer likes OLLI, WMT and FDX -- even after the election.